T. Rowe Price Associates
XFOR icon

T. Rowe Price Associates’s X4 Pharmaceuticals XFOR Stock Holding History

T. Rowe Price Associates’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$310K Buy
+66,379
New +$272K ﹤0.01% 2841
2025
Q2 		– Sell
-2,767
Closed -$20K – 3159
2025
Q1 		$20K Buy
2,767
+900
+48% +$12.4K ﹤0.01% 3005
2024
Q4 		$41K Hold
1,867
– – ﹤0.01% 2962
2024
Q3 		$38K Buy
1,867
+193
+12% +$4.03K ﹤0.01% 2960
2024
Q2 		$30K Buy
1,674
+364
+28% +$11.9K ﹤0.01% 2896
2024
Q1 		$55K Buy
1,310
+417
+47% +$11.6K ﹤0.01% 2863
2023
Q4 		$23K Hold
893
– – ﹤0.01% 2867
2023
Q3 		$30K Buy
893
+59
+7% +$2.57K ﹤0.01% 2832
2023
Q2 		$49K Buy
+834
New +$42.9K ﹤0.01% 2804
2020
Q2 		– Sell
-5,107
Closed -$1.53M – 2542
2020
Q1 		$1.53M Buy
+5,107
New +$1.45M ﹤0.01% 1567

Other funds holding XFOR

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $697M AUM 628.57% 1-Year Est. Return
EAM
Empery Asset Management New York $86.5M AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates's XFOR Position: Q2 2026 in Review

T. Rowe Price Associates opened a new position in X4 Pharmaceuticals (XFOR) in Q2 2026: 66,379 shares worth $310K. The stake represents ﹤0.01% of the portfolio and ranks #2841 among its holdings. This is a return to the name: T. Rowe Price Associates previously reported a position in XFOR as recently as Q1 2025.

T. Rowe Price Associates first reported a position in XFOR in Q1 2020 and has held it in 10 quarters since. The position peaked at $1.53M in Q1 2020. 89 funds tracked by Wall St. Rank hold XFOR as of Q2 2026.

  • T. Rowe Price Associates held 66,379 shares of X4 Pharmaceuticals worth $310K as of Q2 2026.
  • X4 Pharmaceuticals was a new T. Rowe Price Associates position in Q2 2026.
  • X4 Pharmaceuticals made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2841 holding.
  • T. Rowe Price Associates first reported a position in X4 Pharmaceuticals in Q1 2020 and has held it in 10 quarters since.
  • T. Rowe Price Associates's X4 Pharmaceuticals position peaked at $1.53M in Q1 2020.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.